focus -WSS

focus

author：hotspot 2025-09-29 01:36:24 - browse：289

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： How I helped Pfizer think through the ethics of Viagra

knowledge

WSS

A controversial new treatment promises to make little people taller

Biotech startup Celsius cuts 75% of staff ahead of first trial start

The cancer stories no one wants to hear

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Google says AlphaFold 3 can map a vast universe of biomolecules

Study: Adult vaccinations pay for themselves in societal benefits

hotspot

focus

explore

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Apple Watch's A

The high cost of giving birth even with insurance

Readout LOUD podcast: What to know about H5N1 bird flu

How one medical school became remarkably diverse

Chris Christie meets with Zelenskyy during Ukraine trip

United colonoscopy coverage change 'may cost lives,' doctors say

Bird flu outbreak in cows is latest avian flu curveball

DIEP, the 'gold standard' of breast reconstruction, is under threat

CDC wastewater surveillance dashboard to track bird flu hotspots

focus

Shionogi licenses Pompe disease therapy from Maze Therapeutics

H.R. 3 is the wrong path to lower drug costs

Pharma showers House GOP doctor with campaign cash

Alnylam reports growth in sales of rare disease treatments

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Late stage cancers on the rise after pandemic delayed screenings

explore

knowledge

knowledge

entertainment